Maze Therapeutics reported promising Phase 1 clinical trial results for its drug candidate MZE782, targeting metabolic disorders including phenylketonuria and chronic kidney disease. The company is progressing plans to initiate Phase 2 studies for these indications. Following the positive data readout, Maze successfully secured $150 million through a private placement, positioning it to advance the clinical development of MZE782. This represents a significant step for Maze’s metabolic disorder portfolio and highlights growing investor confidence in its pipeline.